WuXi AppTec Co Ltd Asset Resilience Ratio
WuXi AppTec Co Ltd asset resilience ratio. WuXi AppTec Co Ltd (603259) has an Asset Resilience Ratio of 3.51% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of WuXi AppTec Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of WuXi AppTec Co Ltd (2014–2024)
Asset resilience ratio of WuXi AppTec Co Ltd from 2014 to 2024. This chart shows how WuXi AppTec Co Ltd's Asset Resilience Ratio has changed over time. Read WuXi AppTec Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down WuXi AppTec Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 603259 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.94 Billion | 3.51% |
| Total Liquid Assets | CN¥2.94 Billion | 3.51% |
Asset Resilience Insights
- Limited Liquidity: WuXi AppTec Co Ltd maintains only 3.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
WuXi AppTec Co Ltd Industry Peers by Asset Resilience Ratio
Compare WuXi AppTec Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060 |
Diagnostics & Research | 2.10% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Check Cap Ltd
NASDAQ:CHEK |
Diagnostics & Research | 70.29% |
WuXi AppTec Co Ltd Asset Resilience Ratio by Year (2014–2024)
WuXi AppTec Co Ltd asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for WuXi AppTec Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.54% | CN¥1.23 Billion ≈ $180.57 Million |
CN¥80.33 Billion ≈ $11.75 Billion |
+0.47pp |
| 2023-12-31 | 1.07% | CN¥785.78 Million ≈ $114.98 Million |
CN¥73.67 Billion ≈ $10.78 Billion |
+1.06pp |
| 2022-12-31 | 0.00% | CN¥2.00 Million ≈ $292.66K |
CN¥64.69 Billion ≈ $9.47 Billion |
-0.95pp |
| 2021-12-31 | 0.96% | CN¥527.29 Million ≈ $77.16 Million |
CN¥55.13 Billion ≈ $8.07 Billion |
-9.02pp |
| 2020-12-31 | 9.98% | CN¥4.62 Billion ≈ $675.72 Million |
CN¥46.29 Billion ≈ $6.77 Billion |
+4.16pp |
| 2019-12-31 | 5.82% | CN¥1.70 Billion ≈ $249.00 Million |
CN¥29.24 Billion ≈ $4.28 Billion |
-3.56pp |
| 2018-12-31 | 9.38% | CN¥2.13 Billion ≈ $311.00 Million |
CN¥22.67 Billion ≈ $3.32 Billion |
+9.26pp |
| 2017-12-31 | 0.12% | CN¥14.74 Million ≈ $2.16 Million |
CN¥12.58 Billion ≈ $1.84 Billion |
-3.98pp |
| 2016-12-31 | 4.10% | CN¥434.19 Million ≈ $63.54 Million |
CN¥10.59 Billion ≈ $1.55 Billion |
+1.10pp |
| 2015-12-31 | 3.00% | CN¥290.84 Million ≈ $42.56 Million |
CN¥9.69 Billion ≈ $1.42 Billion |
-3.25pp |
| 2014-12-31 | 6.25% | CN¥472.59 Million ≈ $69.15 Million |
CN¥7.56 Billion ≈ $1.11 Billion |
-- |
About WuXi AppTec Co Ltd
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manuf… Read more